Conv. Plasma
Nigella Sativa

All paxlovid studies
Meta analysis
study COVID-19 treatment researchPaxlovidPaxlovid (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   

Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data

Tang et al., International Journal of Clinical Pharmacy, doi:10.1007/s11096-021-01311-5
Jul 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Disproportionality analysis showing higher risk of liver injury with lopinavir/ritonavir for COVID-19 patients. Paxlovid combines nirmatrelvir and ritonavir.
Tang et al., 30 Jul 2021, peer-reviewed, 8 authors. Contact:
This PaperPaxlovidAll
Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data
Huilin Tang, Liyuan Zhou, Xiaotong Li, Alan C Kinlaw, Jeff Y Yang, Andrew M Moon, Edward L Barnes, Tiansheng Wang
International Journal of Clinical Pharmacy, doi:10.1007/s11096-021-01311-5
Background Liver injury has been documented independently in novel coronavirus disease 2019 (COVID-19) patients and patients treated with lopinavir-ritonavir. Objective to investigate the drug-induced liver injury associated with lopinavirritonavir among the patients with COVID-19. Methods We conducted a disproportionality analysis of US Food and Drug Administration Adverse Event Reporting System (FAERS) between 2020Q1 and 2021Q1 to evaluate the association between lopinavir-ritonavir and risk of drug-induced liver injury (or severe drug-induced liver injury) and calculated their reporting odds ratios (RORs) with 95% confidence intervals (CIs). Results A total of 3,425 cases of drug-induced liver injury were reported in 19,782 patients with COVID-19. The ROR for drug-induced liver injury was 2.99 (2.59-3.46), 3.16 (2.68-3.73), and 5.39 (4.63-6.26) when comparing lopinavir-ritonavir with all other drugs, hydroxychloroquine/chloroquine only, and remdesivir, respectively. For severe drug-induced liver injury, RORs for lopinavir-ritonavir provided evidence of an association compared with all other drugs (3.98; 3.15-5.05), compared with hydroxychloroquine/chloroquine only (5.33; 4.09-6.94), and compared with remdesivir (3.85; 3.03-4.89). Conclusions In the FAERS, we observed a disproportional signal for druginduced liver injury associated with lopinavir-ritonavir in patients with COVID-19.
Declarations Conflicts of interest HT is a consultant for Evidpro, LLC. The other authors have no conflict of interest to declare. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Almenoff, Pattishall, Gibbs, Dumouchel, Evans et al., Novel statistical tools for monitoring the safety of marketed drugs, Clin Pharmacol Ther
Cai, Huang, Yu, Zhu, Xia et al., COVID-19: Abnormal liver function tests, J Hepatol
Cao, Wang, Wen, Liu, Wang et al., A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl J Med
Fan, Chen, Li, Cheng, Yang et al., Clinical Features of COVID-19-Related Liver Functional Abnormality, Clin Gastroenterol Hepatol
Gahr, Zeiss, Lang, Connemann, Hiemke et al., Drug-induced liver injury associated with antidepressive psychopharmacotherapy: an explorative assessment based on quantitative signal detection using different MedDRA terms, J Clin Pharmacol
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Nunez, Hepatotoxicity of antiretrovirals: incidence, mechanisms and management, J Hepatol
Olry, Meunier, Delire, Larrey, Horsmans et al., Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same, Drug Saf
Osborne, Davies, Lane, Evans, Denyer et al., Lopinavir-ritonavir in the treatment of COVID-19: a dynamic systematic benefit-risk assessment, Drug Saf
Rochwerg, Agarwal, Siemieniuk, Agoritsas, Lamontagne et al., A living WHO guideline on drugs for covid-19, BMJ
Rothman, Lanes, Sacks, The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol, Drug Saf
Schrezenmeier, Dorner, Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology, Nat Rev Rheumatol
Sherman, Shire, Cernohous, Rouster, Omachi et al., Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir, Clin Infect Dis
Zhang, Shi, Wang, Liver injury in COVID-19: management and challenges, Lancet Gastroenterol Hepatol
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop